Blood pressure variability and risk of new-onset atrial fibrillation: a systematic review of randomized trials of antihypertensive drugs

Increased visit-to-visit variability in blood pressure (BP) is a powerful risk factor for stroke, but the mechanism is uncertain. We hypothesized that BP variability might affect the risk of new atrial fibrillation (AF). We did a systematic review of large randomized controlled trials reporting new-...

Full description

Saved in:
Bibliographic Details
Published in:Stroke (1970) 2010-09, Vol.41 (9), p.2091-2093
Main Authors: Webb, Alastair J S, Rothwell, Peter M
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Atrial Fibrillation - epidemiology
Blood Pressure - drug effects
Blood Pressure - physiology
Humans
Hypertension - drug therapy
Randomized Controlled Trials as Topic
Risk
Risk Assessment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased visit-to-visit variability in blood pressure (BP) is a powerful risk factor for stroke, but the mechanism is uncertain. We hypothesized that BP variability might affect the risk of new atrial fibrillation (AF). We did a systematic review of large randomized controlled trials reporting new-onset AF by treatment allocation, excluding studies in heart failure and acute myocardial infarction. Estimates of the risk of new AF by treatment allocation were related to effects of treatment on group variability in BP. Of 94 eligible randomized controlled trials, 14 reported rates of new AF. Although there was considerable heterogeneity between trials in effects of treatment on variance ratio (P
ISSN:0039-2499
1524-4628
1524-4628
DOI:10.1161/STROKEAHA.110.589531